These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27832018)

  • 1. Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients.
    Poort H; Meade CD; Knoop H; Gielissen MFM; Pinilla-Ibarz J; Jacobsen PB
    Cancer Nurs; 2018; 41(1):E28-E37. PubMed ID: 27832018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial.
    Jim HSL; Hyland KA; Nelson AM; Pinilla-Ibarz J; Sweet K; Gielissen M; Bulls H; Hoogland AI; Jacobsen PB; Knoop H
    Cancer; 2020 Jan; 126(1):174-180. PubMed ID: 31553815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive Behavioral Therapy for Treatment-Related Fatigue in Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitors: A Mixed-Method Study.
    Poort H; Onghena P; Abrahams HJG; Jim HSL; Jacobsen PB; Blijlevens NMA; Knoop H
    J Clin Psychol Med Settings; 2019 Dec; 26(4):440-448. PubMed ID: 30747340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatigue Perpetuating Factors as Mediators of Change in a Cognitive Behavioral Intervention for Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia: A Pilot Study.
    Hyland KA; Nelson AM; Eisel SL; Hoogland AI; Ibarz-Pinilla J; Sweet K; Jacobsen PB; Knoop H; Jim HSL
    Ann Behav Med; 2022 Feb; 56(2):137-145. PubMed ID: 33991085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
    Efficace F; Breccia M; Saussele S; Kossak-Roth U; Cardoni A; Caocci G; Chie W; Naeem A; Nicolatou-Galitis O; Cocks K; Vignetti M; Baccarani M; Mandelli F; Sprangers M
    Ann Hematol; 2012 Sep; 91(9):1371-81. PubMed ID: 22543826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
    Efficace F; Baccarani M; Breccia M; Cottone F; Alimena G; Deliliers GL; Baratè C; Specchia G; Di Lorenzo R; Luciano L; Turri D; Martino B; Stagno F; Dabusti M; Bergamaschi M; Leoni P; Simula MP; Levato L; Fava C; Veneri D; Sica S; Rambaldi A; Rosti G; Vignetti M; Mandelli F
    Leukemia; 2013 Jul; 27(7):1511-9. PubMed ID: 23417029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing a group intervention to manage fatigue in rheumatoid arthritis through modifying physical activity.
    Salmon VE; Hewlett S; Walsh NE; Kirwan JR; Morris M; Urban M; Cramp F
    BMC Musculoskelet Disord; 2019 May; 20(1):194. PubMed ID: 31054567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-Based Intervention (EBI) Mapping: a systematic approach to understanding the components and logic of EBIs.
    Walker TJ; Foster M; Szeszulski J; Craig DW; Mullen PD; Fernández ME
    BMC Public Health; 2022 Jul; 22(1):1300. PubMed ID: 35794615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors.
    Hefner J; Csef EJ; Kunzmann V
    Oncol Nurs Forum; 2017 Nov; 44(6):E232-E240. PubMed ID: 29052661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in chronic myeloid leukemia.
    Trask PC; Cella D; Powell C; Reisman A; Whiteley J; Kelly V
    Leuk Res; 2013 Jan; 37(1):9-13. PubMed ID: 23116602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia.
    Williams LA; Garcia Gonzalez AG; Ault P; Mendoza TR; Sailors ML; Williams JL; Huang F; Nazha A; Kantarjian HM; Cleeland CS; Cortes JE
    Blood; 2013 Aug; 122(5):641-7. PubMed ID: 23777764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of symptom burden on patient quality of life in chronic myeloid leukemia.
    Cella D; Nowinski CJ; Frankfurt O
    Oncology; 2014; 87(3):133-47. PubMed ID: 25012261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy.
    Liu Y; Zhao G; Xu CF; Luo YL; Lu ZD; Wang J
    Biomater Sci; 2018 May; 6(6):1592-1603. PubMed ID: 29725684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient empowerment in the management of chronic myeloid leukemia.
    Coleman M
    Clin J Oncol Nurs; 2014 Apr; 18(2):E12-8. PubMed ID: 24675265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myelogenous leukemia: biology and therapy.
    Gale RP; Grosveld G; Canaani E; Goldman JM
    Leukemia; 1993 Apr; 7(4):653-8. PubMed ID: 8464245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
    Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
    Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis.
    Breccia M; Graffigna G; Galimberti S; Iurlo A; Pungolino E; Pizzuti M; Maggi A; Falzetti F; Capalbo SF; Intermesoli T; Maffioli M; Elena C; Melosi A; Simonetti F; Capochiani E; Seta RD; Pacilli M; Luppi M; Di Renzo N; Mastrullo L; Trabacchi E; Vallisa D; Rapezzi D; Orlandi EM; Gambacorti-Passerini C; Efficace F; Alimena G
    Support Care Cancer; 2016 Nov; 24(11):4487-93. PubMed ID: 27260015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
    Lam MS; Cheung N
    J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
    Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
    J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.